Zevra Therapeutics (ZVRA) Interest Expenses (2014 - 2026)

Zevra Therapeutics' Interest Expenses history runs 13 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• Quarterly Interest Expenses fell 70.65% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 51.25% YoY) and the FY2025 annual result came in at $91.5 million, down 37.48% from the prior year.
• Interest Expenses was $1.7 million for Q1 2026 at Zevra Therapeutics, up from -$2.9 million in the prior quarter.
• Across five years, Interest Expenses topped out at $6.5 million in Q3 2024 and bottomed at -$2.9 million in Q4 2025.
• A 5-year average of $1.7 million and a median of $1.6 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses surged 26440.0% — and 2025, when it plunged 2889.52%.
• Zevra Therapeutics' Interest Expenses stood at $357000.0 in 2022, then sank by 154.06% to -$193000.0 in 2023, then surged by 154.4% to $105000.0 in 2024, then plunged by 2889.52% to -$2.9 million in 2025, then surged by 158.42% to $1.7 million in 2026.
• Business Quant data shows ZVRA's Interest Expenses at $1.7 million in Q1 2026, -$2.9 million in Q4 2025, and $2.1 million in Q3 2025.